What RECONNECT Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |---|---| | Trial name | RECONNECT (Study 301 / Study 302) | | N | 1,247 premenopausal women with HSDD | | Intervention | Bremelanotide 1.75 mg subcutaneous injection, self-administered PRN | | Comparator | Matching placebo injection | | Duration | 24 weeks (double-blind) | | Primary endpoints | Change in desire domain of FSFI; change in FSDS-DAO Item 13 (feeling of distress) | | Key result | Statistically significant improvements in desire (FSFI desire +0.5 vs placebo) and reduced distress (FSDS-DAO Item 13 approximately -0.7 vs placebo) |

Why This Trial Exists

Before RECONNECT, the pharmacologic toolkit for HSDD in premenopausal women consisted of exactly one FDA-approved drug: flibanserin (Addyi), approved in 2015. Flibanserin requires daily dosing, carries a boxed warning against alcohol use, and demands prescriber certification through an REMS program. These restrictions created a gap. Clinicians needed something that could be used on-demand, that did not require daily adherence, and that sidestepped the alcohol interaction problem.

Bremelanotide is a synthetic melanocortin-4 receptor (MC4R) agonist. Rather than modulating serotonin like flibanserin, it acts on central melanocortin pathways involved in sexual arousal. The RECONNECT program (two identically designed Phase 3 trials, 301 and 302) was built to test whether a PRN subcutaneous injection could produce meaningful improvements in desire and reduce the distress that defines HSDD as a diagnosis.

What the Trial Actually Measured

The co-primary endpoints deserve close reading because they reflect a regulatory compromise. The FDA required both a desire measure and a distress measure to clear the bar. Specifically:

• FSFI desire domain score (Female Sexual Function Index, desire subscale, range 1.2 to 6.0)
• FSDS-DAO Item 13 (Female Sexual Distress Scale, Desire/Arousal/Orgasm, single item scoring 0 to 4: "How often did you feel distressed about your level of sexual desire?")

Both endpoints had to show statistical significance for the trial to succeed. This dual-endpoint design is stricter than what many competitor trials use. The RECONNECT investigators reported pooled results across Studies 301 and 302 to power the analysis.

The Enrollment Filter Matters for Practice

RECONNECT enrolled only premenopausal women aged 18 to 55 with generalized, acquired HSDD of at least 6 months' duration. The diagnosis required clinical interview plus validated screening tools. Key exclusions:

• Postmenopausal or perimenopausal women
• Uncontrolled hypertension (systolic >140 or diastolic >90)
• Major depression or active psychiatric illness
• Women using hormonal contraceptives containing only progestins (combined oral contraceptives were permitted)
• Relationship distress as the primary driver of low desire

That last exclusion is worth emphasizing. HSDD is a diagnosis of exclusion in practice: you rule out relationship problems, medication side effects, depression, and hormonal deficiency before you land on it. RECONNECT codified this by screening out women whose low desire was better explained by other factors. In practice, this means the "RECONNECT patient" is a specific phenotype, not the general population of women who report low desire.

Results in Detail

Co-Primary Endpoints (Pooled, 24-Week, ITT)

| Outcome | Bremelanotide (n=630) | Placebo (n=617) | Treatment difference | p-value | |---|---|---|---|---| | FSFI desire domain (LS mean change) | +0.5 | +0.2 | +0.3 | <0.001 | | FSDS-DAO Item 13 (LS mean change) | -0.7 | -0.4 | -0.3 | <0.001 |

Both co-primary endpoints met statistical significance. The effect sizes are modest in absolute terms. A +0.3 difference on a 6-point desire scale is not large. But the FDA's review accepted this because (a) HSDD trials historically produce small between-group differences, (b) the distress reduction was consistent, and (c) a meaningful subset of patients showed clinically significant responses.

Responder Analysis

The responder analysis is where the clinical signal becomes clearer. Across the pooled dataset, roughly 35% of bremelanotide-treated women reported "much improved" or "very much improved" on the Patient Global Impression of Change (PGI-C), compared to about 23% on placebo. That 12-percentage-point spread means approximately 1 in 8 treated women experiences a benefit beyond placebo, a number-needed-to-treat (NNT) of about 8.

Satisfying Sexual Events

Change in satisfying sexual events (SSEs) was a secondary endpoint. Bremelanotide showed a numerical increase over placebo, but the difference did not consistently reach statistical significance across both studies. This is an important caveat: the trial improved desire and reduced distress, but did not reliably increase the frequency of satisfying encounters. Some clinicians view this as evidence that the drug targets subjective experience more than behavioral outcomes.

Safety and Tolerability: The Nausea Problem

The tolerability profile is central to prescribing decisions, and RECONNECT made one thing very clear: nausea is the dominant adverse event.

| Adverse event | Bremelanotide | Placebo | |---|---|---| | Nausea | 40.0% | 1.3% | | Flushing | 20.3% | 1.5% | | Headache | 11.3% | 6.5% | | Injection site reaction | 5.4% | 3.0% |

A 40% nausea rate is high by any standard. In the open-label extension, the nausea rate declined with repeated dosing, suggesting tachyphylaxis of the GI side effect, but 40% of patients experiencing nausea at initiation creates a significant first-dose counseling burden. The Vyleesi prescribing label recommends administration at least 45 minutes before anticipated sexual activity and no more than one dose in 24 hours (maximum 8 doses per month).

Blood pressure effects also warrant attention. Bremelanotide produced transient increases in systolic blood pressure (mean ~3 mmHg) and decreases in heart rate. The label contraindicates use in women with uncontrolled hypertension or known cardiovascular disease. In RECONNECT, no serious cardiovascular events occurred, but the trial excluded the very patients most at risk.

Skin hyperpigmentation was reported in about 1% of bremelanotide-treated patients. The mechanism is logical (melanocortin agonism stimulates melanogenesis), and the labeling warns that hyperpigmentation may not fully resolve after discontinuation.

What Actually Changed in Practice

Guideline Updates

The International Society for the Study of Women's Sexual Health (ISSWSH) updated its HSDD process-of-care algorithm following bremelanotide's FDA approval in June 2019. The algorithm now includes bremelanotide as a treatment option for premenopausal HSDD, positioned alongside flibanserin. The ISSWSH guidelines recommend a biopsychosocial assessment first, followed by pharmacotherapy when non-pharmacologic interventions are insufficient.

The American College of Obstetricians and Gynecologists (ACOG) acknowledged the approval in its clinical guidance but has been more conservative, emphasizing that counseling and psychosexual therapy remain first-line approaches. ACOG's position is that pharmacotherapy should supplement, not replace, addressing modifiable contributing factors.

Prescribing Patterns That Shifted

Three practical patterns emerged after RECONNECT drove Vyleesi to market:

1. PRN dosing changed the conversation. Flibanserin requires daily use for weeks before efficacy can be assessed. Bremelanotide works (or does not work) within a single dose. Clinicians report that some patients strongly prefer knowing whether a drug helps within one or two attempts rather than committing to 8 weeks of daily medication. This is not a superiority claim about efficacy; it is a practical preference that affects adherence.

2. The alcohol restriction gap closed. Flibanserin's REMS-driven alcohol restriction was a deal-breaker for many women. Bremelanotide has no alcohol interaction, no REMS program, and no prescriber certification requirement. For clinicians who found flibanserin's REMS burdensome, bremelanotide offered a lower-friction prescribing pathway.

3. Self-injection remains a barrier. Despite the advantages above, subcutaneous self-injection is unfamiliar territory in sexual medicine. Many patients who would consider a pill decline an autoinjector. Real-world prescription data suggest bremelanotide uptake has been slower than anticipated, in part because of injection reluctance and in part because of inconsistent insurance coverage.

Patients Who Differ from the Trial Population

RECONNECT's narrow enrollment criteria leave several clinical populations without direct evidence.

Postmenopausal women. The trial excluded this group entirely. HSDD is common in postmenopausal women, but the pathophysiology may differ (hormonal deficiency plays a larger role). Bremelanotide is not FDA-approved for postmenopausal HSDD, and no Phase 3 data exist in this population. Clinicians who prescribe it off-label in postmenopausal patients are extrapolating without controlled data.

Women on antidepressants. SSRI/SNRI-induced sexual dysfunction is one of the most common causes of acquired low desire. RECONNECT did not specifically enroll or stratify for antidepressant use. Some women on SSRIs were included, but the trial was not powered to detect a treatment effect in this subgroup. Whether bremelanotide can overcome pharmacologically suppressed desire is unknown from this dataset.

Women with comorbid depression. Active major depression was an exclusion criterion. In practice, HSDD and depression frequently coexist, and disentangling them is difficult. The RECONNECT data do not apply to women with concurrent untreated or undertreated depression.

Cardiovascular risk. The exclusion of uncontrolled hypertension means there are no safety data in this group. The transient BP increases observed in RECONNECT (small but consistent) make this a population where the risk-benefit calculation requires extra caution.

How to Frame This for Patients

The honest framing based on RECONNECT is: bremelanotide modestly improves subjective desire and reduces distress in about 1 in 8 women beyond what placebo achieves. It works within a single dose and does not require daily use. The trade-off is a 40% chance of nausea (which typically lessens with repeated use), self-injection, and a cost that insurance may not cover.

For patients who tried and failed flibanserin, or who cannot tolerate daily dosing or the alcohol restriction, bremelanotide fills a genuine gap. For patients expecting a dramatic shift in sexual desire, the trial data do not support that expectation. Setting calibrated expectations, grounded in the actual RECONNECT numbers rather than marketing language, reduces discontinuation from unmet expectations.

Open Questions RECONNECT Did Not Answer

The 24-week trial duration leaves long-term efficacy and safety open. The open-label extension provided some durability data, but attrition was significant, making interpretation difficult. Whether bremelanotide maintains efficacy over years of PRN use is genuinely unknown.

Head-to-head data against flibanserin do not exist. The two drugs work through different mechanisms (melanocortin vs. serotonin), are dosed differently (PRN vs. daily), and produce different adverse-effect profiles. Indirect comparisons suggest roughly similar effect sizes on desire, but without a randomized comparison, clinicians are choosing based on patient preference, tolerability profile, and practical considerations rather than comparative efficacy data.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
2. U.S. Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. 2019. FDA Label
3. Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93(4):467-487. PubMed
4. American College of Obstetricians and Gynecologists. Female sexual dysfunction: ACOG Practice Bulletin No. 213. Obstet Gynecol. 2019;134(1):e1-e18. PubMed
5. Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. PubMed